Monitor for trial enrollment completion in June 2026 and the eventual top-line data readout in mid-2027. The revenue miss is non-material for a clinical-stage biotech.
Price Chart
Executive Summary
RenovoRx announced management participation in an AGP healthcare showcase and highlighted record Q1 2026 RenovoCath revenue of $563K, missing consensus estimates of $654K. The company also provided an update on its Phase III TIGeR-PaC trial expecting full enrollment by June 2026 and final data in mid-2027. The filing is primarily a routine investor relations event with a modest revenue miss.
Key Financial Metrics
Key Facts
- Record Q1 2026 RenovoCath revenue of $563,000, missing consensus of $654,000
- Expected notification of full enrollment in Phase III TIGeR-PaC trial in early June 2026
- Management to present at AGP Annual Healthcare Company Showcase on May 20, 2026
Financial Impact
Revenue miss of approximately $91,000 (13.9%) against consensus
Risk Factors
- Clinical trial failure or delay
- Cash burn and need for additional financing
- Low liquidity and market cap vulnerability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297484 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $1.27 | awaiting T+60 | — | $1.31 (+3.15%) |
Jul 29, 2026 12w ago | Press Release | $0.8981 $1.27 | ▲ +41.41% | ▲ +36.68% | $1.31 (+45.86%) |
Jul 2, 2026 16w ago | 8-K | $0.9201 $1.68 | ▼ −82.59% | ▼ −79.58% | $1.31 (−42.38%) |
May 26, 2026 21w ago | Press Release | $0.9160 $1.32 | ▲ +43.56% | ▲ +40.83% | $1.31 (+43.01%) |
May 19, 2026 22w ago | Press Release | $0.8060 $1.26 | ▲ +56.33% | ▲ +50.04% | $1.31 (+62.53%) |
May 15, 2026 23w ago | 10-K/A | $0.7830 $1.12 | ▲ +43.04% | ▲ +38.19% | $1.31 (+67.31%) |
May 14, 2026 23w ago | 8-K | $0.8200 $1.15 | ▲ +40.24% | ▲ +35.73% | $1.31 (+59.76%) |
Apr 29, 2026 25w ago | Press Release | $0.8310 $0.8653 | ▲ +4.13% | ▲ +0.02% | $1.31 (+57.64%) |
Apr 28, 2026 26w ago | EFFECT | $0.8400 $0.8545 | ▲ +1.73% | ▼ −2.26% | $1.31 (+55.95%) |
Apr 16, 2026 27w ago | S-3 | $1.00 $0.8500 | ▼ −15.00% | ▼ −21.14% | $1.31 (+31.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers